Dennis Bittner, PhD | Authors


More Endpoints Not Necessarily Merrier in NSCLC Drug Trials

May 13, 2015

The US Food and Drug Administration (FDA) released new guidance on the use of alternative endpoints, in addition to overall survival (OS), for clinical trials of non–small cell lung cancer (NSCLC) therapies.

Liquid Biopsy Use in NSCLC Clinical Practice on the Horizon

February 25, 2015

The definition of liquid biopsy has expanded to include the collection of cfDNA, along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of cancer patients.

Expert Investigators Discuss Emerging Therapies for GI Cancers

February 11, 2015

A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.